The antiviral drug Paxlovid reduces the risk of getting long COVID
It’s not a panacea, but it might be one of the things that can help
The antiviral medication Paxlovid seems to reduce the chance of developing long COVID, researchers report.
In a large study of veterans’ medical records, Paxlovid lowered a person’s chance of landing in the hospital or dying from all causes in the six months following a COVID-19 infection. And the drug reduced the risk of developing 10 of 13 long-term health problems, researchers report March 23 in JAMA Internal Medicine. On average, the drug lowered the relative risk of developing the conditions by 26 percent, says Ziyad Al-Aly, a clinical epidemiologist at Washington University School of Medicine in St. Louis.